Progyny (NASDAQ:PGNY) Updates FY 2026 Earnings Guidance

Progyny (NASDAQ:PGNY) issued an update on its FY 2026 earnings guidance on Thursday. The company provided earnings per share guidance of 2.040-2.100 for the period, compared to the consensus earnings per share estimate of 1.860. The company issued revenue guidance of $1.4 billion-$1.4 billion, compared to the consensus revenue estimate of $1.4 billion. Progyny also updated its Q3 2026 guidance to 0.500-0.520 EPS.

Progyny Stock Down 7.0%

PGNY stock opened at $28.10 on Friday. The company has a market cap of $2.20 billion, a P/E ratio of 30.54, a PEG ratio of 2.40 and a beta of 1.01. Progyny has a twelve month low of $16.10 and a twelve month high of $33.06. The business has a fifty day moving average of $29.08 and a 200-day moving average of $23.43.

Progyny (NASDAQ:PGNY) last posted its quarterly earnings results on Thursday, May 7th. The company reported $0.50 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.26 by $0.24. The business had revenue of $328.50 million for the quarter, compared to analysts’ expectations of $326.46 million. Progyny had a return on equity of 15.57% and a net margin of 6.00%.The firm’s quarterly revenue was down 26.4% compared to the same quarter last year. During the same quarter last year, the business earned $0.17 earnings per share. As a group, equities research analysts anticipate that Progyny will post 1.19 earnings per share for the current fiscal year.

Progyny announced that its Board of Directors has authorized a stock buyback program on Tuesday, May 26th that permits the company to buyback $200.00 million in shares. This buyback authorization permits the company to repurchase up to 10.3% of its shares through open market purchases. Shares buyback programs are often a sign that the company’s management believes its stock is undervalued.

Analysts Set New Price Targets

PGNY has been the topic of a number of research reports. Barclays restated an “equal weight” rating and set a $34.00 target price (up from $27.00) on shares of Progyny in a research report on Tuesday, July 28th. Weiss Ratings raised shares of Progyny from a “hold (c-)” rating to a “hold (c)” rating in a research note on Friday, June 26th. Citizens Jmp boosted their price target on shares of Progyny from $30.00 to $31.00 and gave the stock a “market outperform” rating in a research note on Monday, May 11th. Bank of America increased their price objective on shares of Progyny from $29.00 to $31.00 and gave the company a “buy” rating in a report on Tuesday, June 2nd. Finally, KeyCorp raised their price objective on shares of Progyny from $30.00 to $35.00 and gave the company an “overweight” rating in a research note on Monday, July 13th. One equities research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat.com, Progyny presently has an average rating of “Moderate Buy” and an average price target of $34.20.

Insider Activity at Progyny

In related news, EVP Allison Swartz sold 1,199 shares of the company’s stock in a transaction on Wednesday, June 3rd. The shares were sold at an average price of $25.02, for a total value of $29,998.98. Following the completion of the transaction, the executive vice president directly owned 83,316 shares of the company’s stock, valued at approximately $2,084,566.32. This represents a 1.42% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Geoffrey Clapp sold 1,530 shares of the company’s stock in a transaction on Tuesday, June 2nd. The stock was sold at an average price of $25.58, for a total transaction of $39,137.40. Following the completion of the transaction, the insider directly owned 59,117 shares of the company’s stock, valued at approximately $1,512,212.86. The trade was a 2.52% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 36,916 shares of company stock valued at $939,875 over the last three months. Insiders own 9.90% of the company’s stock.

Key Progyny News

Here are the key news stories impacting Progyny this week:

• Positive Sentiment: Progyny reported second-quarter earnings of $0.55 per share, well above the $0.33 consensus estimate, while revenue of $350.5 million modestly exceeded expectations of $348.6 million. Revenue increased 5.3% year over year, and earnings improved from $0.19 per share in the prior-year quarter. Progyny Announces Second Quarter 2026 Results
• Positive Sentiment: Full-year 2026 adjusted EPS guidance of $2.04 to $2.10 is above the analyst consensus of $1.86, signaling confidence in profitability. Full-year revenue guidance of approximately $1.4 billion is broadly in line with expectations. Progyny Q2 Earnings and Revenues Beat Estimates
• Neutral Sentiment: CEO Pete Anevski is scheduled to present at the Canaccord Genuity Annual Growth Conference on August 11. The event could provide additional detail on client demand, growth initiatives and the company’s outlook, but it does not immediately change financial results. Progyny to Present at Canaccord Genuity Conference
• Negative Sentiment: Third-quarter revenue guidance of $335 million to $345 million is below the $350.2 million analyst consensus. Although projected EPS of $0.50 to $0.52 exceeds the $0.47 consensus, investors appear more concerned about slower top-line momentum and the possibility that growth remains muted. Why Progyny Shares Are Sliding Today

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of PGNY. Caitong International Asset Management Co. Ltd acquired a new stake in Progyny in the 4th quarter valued at approximately $25,000. Canada Pension Plan Investment Board bought a new stake in Progyny in the 2nd quarter valued at approximately $77,000. Quarry LP boosted its position in Progyny by 2,004.1% during the 3rd quarter. Quarry LP now owns 3,598 shares of the company’s stock worth $77,000 after acquiring an additional 3,427 shares during the last quarter. Tower Research Capital LLC TRC boosted its position in Progyny by 203.5% during the 2nd quarter. Tower Research Capital LLC TRC now owns 7,021 shares of the company’s stock worth $154,000 after acquiring an additional 4,708 shares during the last quarter. Finally, Entropy Technologies LP bought a new position in shares of Progyny during the 4th quarter worth approximately $203,000. 94.93% of the stock is owned by institutional investors and hedge funds.

Progyny Company Profile

Progyny, Inc is a New York-based fertility benefits management company that partners with employers and health plans to design and administer comprehensive family-building programs. The company’s digital health platform integrates clinical expertise, patient support tools and data analytics to help members navigate fertility treatments, from in vitro fertilization (IVF) and egg freezing to surrogacy and adoption. By focusing on outcomes-based care, Progyny aims to improve success rates while controlling costs for its clients.

The core of Progyny’s offering is its proprietary Smart Cycle® benefit, which bundles clinical, emotional and logistical support into a single package.